GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: compound 4b [PMID: 28124907] | GS-5734 | GS5734 | Veklury®
                                 remdesivir is an approved drug (FDA & EMA (2020)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Remdesivir (GS-5734) is a nucleotide analogue drug that was developed by Gilead Sciences for antiviral potential, in particular for anti-Ebola and anti-Marburg virus activity [7]. It acts is an inhibitor of the viral RNA-dependent RNA polymerase (RdRP) that functions as a chain terminator during viral RNA synthesis.  Remdesivir is a prodrug whose major active metabolite is GS-441524.  Its 1'-CN group and C-linked nucleobase ensure optimal anti-Ebola potency and selectivity against host polymerase enzymes. Remdesivir has broad-spectrum activity against several viral families such as filoviruses, paramyxoviruses, and coronaviruses, and including the SARS and MERS coronaviruses (CoVs), endemic circulating human CoVs, and against SARS-CoV-2 [1-2,6]. The first patient to test positive for SARS-CoV-2 in the US was treated with i.v. remdesivir (using compassionate use of an investigational therapy prescribing) and his clinical condition improved significantly within the next 24h without observation of adverse effects [4].
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| Classification  | |
| Compound class | Synthetic organic | 
| Approved drug? | Yes. EU EMA (2020) | US FDA (2020) | 
| Is prodrug? | Yes | 
| Active form | GS-441524 | 
| IUPAC Name  | 
| 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 10478 | remdesivir | 
| Synonyms  | 
| compound 4b [PMID: 28124907] | GS-5734 | GS5734 | Veklury® | 
| Database Links  | |
| Specialist databases | |
| Reactome Drug   | R-ALL-9680278 | 
| Reactome Reaction   | R-HSA-9687384, R-HSA-9687388, R-HSA-9680262, R-HSA-9694665, R-HSA-9694541, R-HSA-9694419 | 
| Other databases | |
| CAS Registry No. | 1809249-37-3 (source: WHO INN record) | 
| ChEMBL Ligand | CHEMBL4065616 | 
| DrugCentral Ligand | 5376 | 
| GtoPdb PubChem SID | 404859162 | 
| PubChem CID | 121304016 | 
| Search Google for chemical match using the InChIKey | RWWYLEGWBNMMLJ-YSOARWBDSA-N | 
| Search Google for chemicals with the same backbone | RWWYLEGWBNMMLJ | 
| Search PubMed clinical trials | remdesivir | 
| Search PubMed titles | remdesivir | 
| Search PubMed titles/abstracts | remdesivir | 
| UniChem Compound Search for chemical match using the InChIKey | RWWYLEGWBNMMLJ-YSOARWBDSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | RWWYLEGWBNMMLJ-YSOARWBDSA-N | 
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖| 
                                                                           
                                                                           Remdesivir (links to external site) Cat. No. HY-104077 |